课题基金 / 基金详情

RIBOZYME GENE THERAPY FOR HIV-1 INFECTION

RIBOZYME GENE THERAPY FOR HIV-1 INFECTION
HIV-1 感染的核酶基因疗法
批准号：
6117937
负责人：
Flossie Wong-Staal
金额：
$1.46万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN DIEGO
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6117937
关键词：
AIDS therapy HIV infections Retroviridae T lymphocyte clinical research gene expression gene therapy genetic transduction human subject nucleic acid sequence phenotype recombinant proteins ribozymes tissue /cell culture transfection /expression vector

项目摘要

项目成果

Flossie Wong-Staal的其他基金

相似基金

相关文献

中文摘要
翻译
确定将体外转导的自体淋巴细胞与带有HIV-1前导序列发夹状核酶的逆转录病毒载体注射的安全性。比较核酶转导细胞和对照载体转导细胞的体内动力学和存活情况，描绘基因改变的T细胞的隔离和存活情况，测定核酶在转导淋巴细胞中的体内表达，并对基因治疗的效果进行初步观察。
英文摘要
Determine the safety of infusing autologous lymphocytes that have been transduced ex vivo with a retroviral vector bearing an HIV-1 leader sequence hairpin ribozyme. Compare in vivo kinetics and survival of ribozyme-transduced cells with a separate aliquot of cells transduced with a control vector, delineate sequestration and survival of gene-altered t-cells, determine in vivo expression of ribozyme in transduced lymphocytes and make preliminary observations on the effects of gene therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Investigation of the Potential Anti-Diabetic Activity of ITX2158 In Vivo
  • 批准号：
    7608527
  • 项目类别：
  • 资助金额：
    $15.32万
  • 财政年份：
    2009
  • 负责人：
    Flossie Wong-Staal
  • 依托单位：
    ITHERX PHARMACEUTICALS, INC.
Development of HIV vectors for antiviral and immune based therapies
Development of HIV vectors for antiviral and immune based therapies
Development of HIV vectors for antiviral and immune based therapies
海外基金